SecBot SecBot
SECBOTREPLAY Home › Report › ESPR

ESPR · Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc…

Esperion Therapeutics, Inc. · PRESS-RELEASE filed May 26, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed May 26, 2026 at 08:00 ET

Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid reduced LDL-C in children (range 6-25%) without new safety concerns, and that 42% of statin-intolerant adults achieved ≥30% LDL-C reduction. These data support ongoing Phase 3 pediatric studies and reinforce the product profile, but are interim scientific presentations without a hard regulatory catalyst or financial update.

  • Phase 2 study in children aged 6-17 with HeFH showed weight-based bempedoic acid dosing produced adult-equivalent exposure and LDL-C reductions of 6-25% with no new safety signals.
  • CLEAR Outcomes post-hoc analysis: 42% of statin-intolerant adults on bempedoic acid achieved ≥30% LDL-C reduction at 3 months, comparable to moderate-intensity statins.
  • Factors associated with ≥30% LDL-C reduction included female sex, higher baseline LDL-C, and concurrent ezetimibe use.
  • No new regulatory approvals, label expansions, financial results, or guidance were announced in this press release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access